Statistics for Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Total visits
| views | |
|---|---|
| Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine | 2 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 2 |
| May 2025 | 0 |
| June 2025 | 0 |
Top country views
| views | |
|---|---|
| United States | 2 |
Top city views
| views | |
|---|---|
| Greenwood | 2 |